Claims for Patent: 5,872,241

Summary for Patent: 5,872,241

Title:	Multiple component RNA catalysts and uses thereof
Abstract:	This invention is directed to a composition for catalyzed oligonucleotide cleavage comprising a synthetic non-naturally occurring oligonucleotide compound. The compound comprises nucleotides whose sequence defines a conserved group II intron catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined oligonucleotide target sequence to be cleaved, such target sequence not being present within the compound. The composition also includes an appropriate oligonucleotide co-factor. Preferably, the conserved group II intron catalytic region is a group II intron domain I catalytic region. In one embodiment the conserved group II intron domain I catalytic region may further comprise a conserved portion of a group II intron domain II, a group II intron domain III, a group II intron domain IV, a group II intron domain V, or a group II intron domain VI. The invention is also directed to methods of treatment and methods of use of such compounds.
Inventor(s):	Pyle; Anna M. (New York, NY), Michels; William J. (New York, NY)
Assignee:	The Trustees of Columbia University in the City of New York (New York, NY)
Application Number:	08/378,235
Patent Claims:	1. A synthetic non-naturally occurring nucleic acid molecule comprising: a) nucleotides hating a sequence which defines a conserved group II intron catalytic region; b) nucleotides having a sequence which hybridizes with a predetermined target sequence to be cleaved, and c) nucleotides having a sequence which defines a conserved portion of a group II intron domain V. 2. The molecule of claim 1, wherein the conserved group II intron catalytic region is a group II intron domain I catalytic region. 3. The molecule of claim 2, wherein the conserved group II intron domain I catalytic region further comprises a conserved portion of a group II intron domain II, a group II intron domain III, a group II intron domain IV, a group II intron domain V, or a group II intron domain VI. 4. The molecule of claim 1, wherein the sequence of part (b) is 2 to 12 nucleotides in length. 5. The molecule of claim 1, wherein the sequence of part (b) is 6 or 7 nucleotides in length. 6. The molecule of claim 1, wherein the molecule comprises from about 80 nucleotides to about 1000 nucleotides. 7. The molecule of claim 1, wherein the conserved portion of the group II intron domain V has the formula: ##STR2## (Seq. ID No. 3) wherein each X represents a ribonucleotide which may be the same or different; wherein each of (X).sub.n, (X).sub.n', (X).sub.c, (X).sub.c', (X).sub.d', (X).sub.a and (X).sub.d represents an oligonucleotide; wherein n, n', c, c', d, d', and a each represents an integer which defines the number of nucleotides in the oligonucleotide with the provisos that n and n' are greater than or equal to 1; a represents an integer which is greater than or equal to 1; d and d' represent an integer which is greater than or equal to 5; c and c' represents an integer which is greater than or equal to 4; wherein each * represents base pairing between the nucleotide located on either side thereof; wherein each .dagger-dbl. may or may not represent base pairing between the nucleotide located on either side thereof; and wherein each solid line represents a chemical linkage providing covalent bonds between the nucleotide located on either side thereof. 8. The molecule of claim 1, further comprising an associated divalent cation. 9. The molecule of claim 1, wherein the divalent cation is Mg.sup.2+ or Mn.sup.2+. 10. The molecule of claim 1, wherein the predetermined target sequence to be cleaved is DNA. 11. The molecule of claim 1, wherein the predetermined target sequence to be cleaved is mRNA. 12. The molecule of claim 11, wherein the mRNA encodes a growth factor. 13. The molecule of claim 12, wherein the growth factor is an angiogenic factor, a basic fibroblast growth factor, a colony-stimulating factor 1, cystic fibrosis transmembrane conductance regulator, an epidermal growth factor, an erythropoietin, a fibroblast growth factor, a G-protein, a granulocyte-macrophage colony stimulating factor, a growth hormone, IL-1, IL-LR, IL-2, IL-2R, IL-4, IL-6, an insulin-like growth factor, an insulin-like growth factor 1, an interferon, an interleukin, a keratinocyte growth factor, luteinizing hormone receptor, MDR1, a nerve growth factor, a platelet derived growth factor, a scatter factor, a transforming growth factor .alpha., a transforming growth factor .beta., a transforming growth factor, or a tumor necrosis factor. 14. The molecule of claim 11, wherein the mRNA encodes an oncogene or a tumor suppressor gene. 15. The molecule of claim 14, wherein the oncogene or tumor suppressor gene is bcl-2, bcr-abl, bek, BPV, c-abl, c-fes, c-fms, c-fos, c-H-ras, c-kit, c-myb, c-myc, c-mos, c-sea, cerbB, DCC, erbA, erbB-2, ets, fig, FSFV gp55, Ha-ras, HIV tat, HTLV-1 tat, JCV early, jun, L-myc, lck, LPV early, met, N-myc, NF-1, N-ras, neu, p53, Py mTag, pim-1, ras, RB, rel, retinoblastoma-1, SV-40 Tag, TGF-.alpha., TGF-.beta., trk, trkB, v-abl, v-H-ras, v-jun, or WT-1. 16. The molecule of claim 11, wherein the mRNA is an mRNA associated with a chromosomal translocation. 17. The molecule of claim 14, wherein the oncogene or tumor suppressor gene has one or more point mutations. 18. The molecule of claim 11, wherein the mRNA is an mRNA whose overproduction is associated with a disease or neoplastic condition. 19. The molecule of claim 11, wherein the mRNA is a mammalian mRNA. 20. The molecule of claim 11, wherein the mRNA is a yeast mRNA. 21. A synthetic non-naturally occurring nucleic acid molecule comprising: a) nucleotides having a sequence which defines a conserved group II intron catalytic region, b) two regions of nucleotides each having a sequence which hybridizes with a predetermined target sequence to be cleaved, and c) nucleotides having a sequence which defines a conserved portion of a group II intron domain V. 22. A composition comprising: a) a synthetic non-naturally occurring nucleic acid molecule comprising: i) nucleotides having a sequence which defines a conserved group II intron catalytic region, and ii) nucleotides having a sequence which hybridizes with a predetermined target sequence to be cleaved; and b) a separate nucleotide sequence which defines a conserved portion of a group II intron domain V.

Details for Patent 5,872,241

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26